menu
    • menu
    [{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Developmental Therapeutics Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Elraglusib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Developmental Therapeutics Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Developmental Therapeutics Consortium"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Elraglusib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elraglusib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Actuate Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elraglusib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Actuate Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elraglusib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Actuate Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elraglusib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Actuate Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||GSK-3 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||GSK 3-beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Elraglusib

    Menu

    Elraglusib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elraglusib,Losartan Potassium,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Actuate Completes Enrollment in Phase 2 Elraglusib Trial for Pancreatic Cancer

                            Details : 9-ING-41 (elraglusib), a novel GSK-3 inhibitor, targets molecular pathways in cancer that are involved in promoting tumor growth. It is being investigated for metastatic pancreatic cancer.

                            Product Name : 9-ING-41

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 25, 2025

                            Lead Product(s) : Elraglusib,Losartan Potassium,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elraglusib,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Actuate Therapeutics Receives EMA Orphan Status for Elraglusib in Pancreatic Cancer

                            Details : 9-ING-41 (elraglusib), a novel GSK-3 inhibitor, targets molecular pathways in cancer that are involved in promoting tumor growth. It is being investigated for metastatic pancreatic cancer.

                            Product Name : 9-ING-41

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 07, 2025

                            Lead Product(s) : Elraglusib,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elraglusib,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Actuate Shows Positive Interim Data for Elraglusib in Metastatic Pancreatic Cancer

                            Details : 9-ING-41 (elraglusib), a novel GSK-3 inhibitor, targets molecular pathways in cancer that are involved in promoting tumor growth. It is being investigated for metastatic pancreatic cancer.

                            Product Name : 9-ING-41

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 17, 2024

                            Lead Product(s) : Elraglusib,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elraglusib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Actuate Receives FDA Rare Pediatric Disease Designation for Elraglusib

                            Details : 9-ING-41 (elraglusib), a novel GSK-3 inhibitor, targets molecular pathways in cancer that are involved in promoting tumor growth. It is being investigated for Ewing sarcoma.

                            Product Name : 9-ING-41

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 12, 2024

                            Lead Product(s) : Elraglusib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elraglusib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Actuate Receives FDA Orphan Drug Designation For Elraglusib in Sarcomas

                            Details : Actuate’s lead investigational drug product, 9-ING-41 (elraglusib), a novel GSK-3 inhibitor, targets molecular pathways in cancer that are involved in promoting tumor growth.

                            Product Name : 9-ING-41

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 11, 2024

                            Lead Product(s) : Elraglusib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elraglusib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Actuate Provides Update on Elraglusib Trial for Relapsed/Refractory Ewing Sarcoma

                            Details : Actuate’s lead investigational drug product, 9-ING-41 (elraglusib), a novel GSK-3 inhibitor, targets molecular pathways in cancer that are involved in promoting tumor growth.

                            Product Name : 9-ING-41

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 09, 2024

                            Lead Product(s) : Elraglusib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elraglusib,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Actuate Therapeutics Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Pancreatic Cancer

                            Details : 9-ING-41 (elraglusib) is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is being developed for adults and children with advanced refractory pancreatic cancer cancer.

                            Product Name : 9-ING-41

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 01, 2023

                            Lead Product(s) : Elraglusib,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Actuate Therapeutics, Inc

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elraglusib,Retifanlimab,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Developmental Therapeutics Consortium

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlima...

                            Details : 9-ING-41 (elraglusib), a small molecule glycogen synthase kinase-3 beta combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity ...

                            Product Name : 9-ING-41

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2022

                            Lead Product(s) : Elraglusib,Retifanlimab,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Developmental Therapeutics Consortium

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth